Free express AUS and US shipping for orders above $200 • Subscribe to receive 10% off

SS-31 25mg

$99.00

SS-31 (Elamipretide or MTP-131) is a synthetic tetrapeptide that selectively targets the inner mitochondrial membrane by binding to cardiolipin, a unique phospholipid essential for mitochondrial structure. Through this interaction, SS-31 stabilizes mitochondrial cristae, promotes efficient electron transport chain function, and enhances ATP production while reducing reactive oxygen species (ROS). It also prevents the opening of the mitochondrial permeability transition pore (mPTP), thereby protecting cells from oxidative stress and apoptosis.

This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

In Stock

Data Sheet

Molecular Formula C32H49N9O5
CAS Number 736992-21-5
Molar Mass 639.802 g/mol
Amino Acid Sequence D-Arg-Dmt-Lys-Phe-NH2
PubChem CID 11764719
Primary Research Area Renal aging and mitochondrial dysfunction.
Mitochondrial bioenergetics and inflammation.
Neurodegenerative disease and mitochondrial protection.
Cardiac metabolism and mitochondrial cardiomyopathy.
Diabetic nephropathy and oxidative stress.
Chronic kidney disease
Ototoxicity prevention and mitochondrial drug delivery.
Research Summary Description
The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age Summary:This study demonstrated that SS-31 administration in aged mice restored mitochondrial function within renal glomeruli, reduced oxidative stress, and improved podocyte integrity. Treatment resulted in preserved glomerular structure and overall kidney function.

Implication: These findings suggest that SS-31 may serve as a therapeutic agent for age-associated renal decline by stabilizing mitochondrial function and mitigating oxidative injury in kidney tissues.

Citation: Sweetwyne, M. T., Pippin, J. W., Eng, D. G., Hudkins, K. L., Chiao, Y. A., Campbell, M. D., ... & Shankland, S. J. (2017). The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age. Kidney international, 91(5), 1126-1145.
Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH 2) derivatives as potent agents to ameliorate inflammation and increase mitochondrial ATP synthesis Summary:Researchers synthesized new SS-31 derivatives with improved efficacy. These analogs enhanced mitochondrial ATP production and displayed stronger anti-inflammatory properties compared to the parent peptide.

Implication: This study highlights the potential of optimizing SS-31’s structure to develop more potent mitochondria-targeted therapeutics for metabolic and inflammatory diseases.

Citations: Li, M., Kong, D., Meng, L., Wang, Z., Bai, Z., & Wu, G. (2024). Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH 2) derivatives as potent agents to ameliorate inflammation and increase mitochondrial ATP synthesis. RSC advances, 14(41), 29789-29799.
Therapeutic peptide SS-31 modulates membrane binding and aggregation of α-synuclein and restores impaired mitochondrial function Summary:SS-31 was shown to interfere with α-synuclein membrane binding and aggregation, processes linked to mitochondrial dysfunction in neurodegenerative diseases. The peptide restored mitochondrial integrity and energy metabolism in affected cells.

Implication: SS-31 demonstrates neuroprotective potential, offering a therapeutic avenue for conditions such as Parkinson’s disease by preventing protein aggregation and preserving mitochondrial health.

Citation: Stefaniak, E., Cui, B., Sun, K., Yan, X., Teng, X., & Ying, L. (2024). Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function. bioRxiv, 2024-07.
Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice Summary:In a tafazzin-deficient mouse model, SS-31 improved cardiac mitochondrial structure, enhanced ATP production, and reduced oxidative damage, leading to better cardiac performance.

Implication: SS-31 may represent a promising treatment for mitochondrial cardiomyopathies, such as Barth syndrome, by restoring mitochondrial bioenergetics and cardiac function.

Citations: Russo, S., De Rasmo, D., Signorile, A., Corcelli, A., & Lobasso, S. (2022). Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice. Scientific Reports, 12(1), 19847.
Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy Summary: SS-31 treatment in diabetic mice reduced renal oxidative stress, inflammation, and fibrosis while improving mitochondrial respiration and kidney morphology.

Implication: These results indicate that SS-31 can be a potential therapeutic candidate for diabetic nephropathy through its antioxidant and mitochondrial-protective mechanisms.

Citations:Hou, Y., Li, S., Wu, M., Wei, J., Ren, Y., Du, C., ... & Shi, Y. (2016). Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy. American Journal of Physiology-Renal Physiology, 310(6), F547-F559.
SS-31, a mitochondria-targeting peptide, ameliorates kidney disease Summary:This study confirmed SS-31’s renoprotective effects by demonstrating decreased mitochondrial damage, reduced inflammatory responses, and improved renal function in kidney disease models.

Implication: SS-31’s mitochondria-targeting mechanism offers a promising strategy for treating chronic kidney disease by maintaining mitochondrial stability and cellular homeostasis.

Citations: Zhu, Y., Luo, M., Bai, X., Li, J., Nie, P., Li, B., & Luo, P. (2022). SS‐31, a mitochondria‐targeting peptide, ameliorates kidney disease. Oxidative Medicine and Cellular Longevity, 2022(1), 1295509.
SS-31 peptide enables mitochondrial targeting drug delivery: a promising therapeutic alteration to prevent hair cell damage from aminoglycosides Summary:The study showed that SS-31 can facilitate targeted drug delivery to mitochondria in cochlear hair cells, reducing aminoglycoside-induced oxidative damage and preventing cell death.

Implication: This research supports SS-31 as a novel platform for mitochondrial drug delivery and a potential therapeutic tool for preventing ototoxicity and hearing loss associated with antibiotic use.

Citation: Kuang, X., Zhou, S., Guo, W., Wang, Z., Sun, Y., & Liu, H. (2017). SS-31 peptide enables mitochondrial targeting drug delivery: a promising therapeutic alteration to prevent hair cell damage from aminoglycosides. Drug Delivery, 24(1), 1750-1761.

The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age

Summary:This study demonstrated that SS-31 administration in aged mice restored mitochondrial function within renal glomeruli, reduced oxidative stress, and improved podocyte integrity. Treatment resulted in preserved glomerular structure and overall kidney function.

Implication: These findings suggest that SS-31 may serve as a therapeutic agent for age-associated renal decline by stabilizing mitochondrial function and mitigating oxidative injury in kidney tissues.

Citation: Sweetwyne, M. T., Pippin, J. W., Eng, D. G., Hudkins, K. L., Chiao, Y. A., Campbell, M. D., ... & Shankland, S. J. (2017). The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age. Kidney international, 91(5), 1126-1145.

Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH 2) derivatives as potent agents to ameliorate inflammation and increase mitochondrial ATP synthesis

Summary:Researchers synthesized new SS-31 derivatives with improved efficacy. These analogs enhanced mitochondrial ATP production and displayed stronger anti-inflammatory properties compared to the parent peptide.

Implication: This study highlights the potential of optimizing SS-31’s structure to develop more potent mitochondria-targeted therapeutics for metabolic and inflammatory diseases.

Citations: Li, M., Kong, D., Meng, L., Wang, Z., Bai, Z., & Wu, G. (2024). Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH 2) derivatives as potent agents to ameliorate inflammation and increase mitochondrial ATP synthesis. RSC advances, 14(41), 29789-29799.

Therapeutic peptide SS-31 modulates membrane binding and aggregation of α-synuclein and restores impaired mitochondrial function

Summary:SS-31 was shown to interfere with α-synuclein membrane binding and aggregation, processes linked to mitochondrial dysfunction in neurodegenerative diseases. The peptide restored mitochondrial integrity and energy metabolism in affected cells.

Implication: SS-31 demonstrates neuroprotective potential, offering a therapeutic avenue for conditions such as Parkinson’s disease by preventing protein aggregation and preserving mitochondrial health.

Citation: Stefaniak, E., Cui, B., Sun, K., Yan, X., Teng, X., & Ying, L. (2024). Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function. bioRxiv, 2024-07.

Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice

Summary:In a tafazzin-deficient mouse model, SS-31 improved cardiac mitochondrial structure, enhanced ATP production, and reduced oxidative damage, leading to better cardiac performance.

Implication: SS-31 may represent a promising treatment for mitochondrial cardiomyopathies, such as Barth syndrome, by restoring mitochondrial bioenergetics and cardiac function.

Citations: Russo, S., De Rasmo, D., Signorile, A., Corcelli, A., & Lobasso, S. (2022). Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice. Scientific Reports, 12(1), 19847.

Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy

Summary: SS-31 treatment in diabetic mice reduced renal oxidative stress, inflammation, and fibrosis while improving mitochondrial respiration and kidney morphology.

Implication: These results indicate that SS-31 can be a potential therapeutic candidate for diabetic nephropathy through its antioxidant and mitochondrial-protective mechanisms.

Citations:Hou, Y., Li, S., Wu, M., Wei, J., Ren, Y., Du, C., ... & Shi, Y. (2016). Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy. American Journal of Physiology-Renal Physiology, 310(6), F547-F559.

SS-31, a mitochondria-targeting peptide, ameliorates kidney disease

Summary:This study confirmed SS-31’s renoprotective effects by demonstrating decreased mitochondrial damage, reduced inflammatory responses, and improved renal function in kidney disease models.

Implication: SS-31’s mitochondria-targeting mechanism offers a promising strategy for treating chronic kidney disease by maintaining mitochondrial stability and cellular homeostasis.

Citations: Zhu, Y., Luo, M., Bai, X., Li, J., Nie, P., Li, B., & Luo, P. (2022). SS‐31, a mitochondria‐targeting peptide, ameliorates kidney disease. Oxidative Medicine and Cellular Longevity, 2022(1), 1295509.

SS-31 peptide enables mitochondrial targeting drug delivery: a promising therapeutic alteration to prevent hair cell damage from aminoglycosides

Summary:The study showed that SS-31 can facilitate targeted drug delivery to mitochondria in cochlear hair cells, reducing aminoglycoside-induced oxidative damage and preventing cell death.

Implication: This research supports SS-31 as a novel platform for mitochondrial drug delivery and a potential therapeutic tool for preventing ototoxicity and hearing loss associated with antibiotic use.

Citation: Kuang, X., Zhou, S., Guo, W., Wang, Z., Sun, Y., & Liu, H. (2017). SS-31 peptide enables mitochondrial targeting drug delivery: a promising therapeutic alteration to prevent hair cell damage from aminoglycosides. Drug Delivery, 24(1), 1750-1761.

All content and product details on this website are provided solely for informational and educational purposes.

View Cart (0 items)

Your cart is empty

Start Shopping